Mereo is a new UK-based speciality biopharmaceutical company focussed on the acquisition and rapid development of innovative medicines that have the potential to transform patient quality of life and improve human health. Mereo intends to optimise the commercial value of programmes by entering into partnering deals at key value inflection points or, for selected opportunities, commercialising products itself. Mereo is building a strong pipeline of innovative medicines, particularly focused in rare and specialist disease areas, through the acquisition of validated, mid-stage development programmes from large biopharmaceutical companies. Mereo has access to an extensive network of experts with experience across multiple clinical disciplines and has entered into a strategic development partnership with ICON, a leading global contract research organisation (CRO), for the clinical development of its portfolio.